24/7 Market News Snapshot 29 July, 2025 – Exagen Inc. Common Stock (NASDAQ:XGN)
DENVER, Colo., 29 July, 2025 (www.247marketnews.com) – (Nasdaq:XGN) are discussed in this article.
Exagen Inc. (Nasdaq:XGN) has demonstrated strong market performance today, beginning at $7.97 and reaching a trading price of $8.64, which marks a significant increase of approximately 16.91% from the previous day’s closing price of $7.39. The trading volume has surged to 804.41K shares, signaling heightened investor interest and potential for continued price fluctuations. This upward momentum may reflect bullish sentiment among traders, possibly due to favorable company developments or market catalysts, warranting close scrutiny of support and resistance levels to forecast future price movements.
In conjunction with its market performance, Exagen has revealed impressive financial results for the second quarter of 2025, with total revenues hitting $17.2 million. This represents an 11% increase from the previous quarter and a 14% rise year-over-year. The uptick in revenue was buoyed by a 14% increase in the volume of the AVISE CTD tests, showcasing an escalating demand for the company’s diagnostic solutions. Exagen also reported a gross margin of 60.4%, marginally above the previous year’s figure of 60.1%, reflecting the company’s solid pricing power, with the trailing twelve-month average selling price for the AVISE CTD moving up to $428.
To strengthen its operational capacity, Exagen completed a public offering raising $20.2 million and secured a new loan credit facility, concluding the quarter with cash and equivalents totaling $30.2 million. Moreover, the appointment of Dr. Michael Mahler as Chief Scientific Officer and Chas McKhann to the Board of Directors highlights Exagen’s commitment to enhancing its strategic direction.
Looking forward, Exagen projects full-year 2025 revenues between $65 million and $70 million, anticipating the potential for positive adjusted EBITDA in the fourth quarter. The company remains focused on its mission to improve care for patients with autoimmune disorders through innovative testing solutions.